[{"indications": "Indications\u00a0oedema\r\nand ascites in cirrhosis of the liver; malignant ascites; nephrotic\r\nsyndrome; oedema in congestive heart failure; moderate to severe heart\r\nfailure (adjunct\u2014see also section 2.5.5); resistant hypertension [unlicensed\r\nindication] (adjunct\u2014see also section 2.5); treatment\r\nof primary hyperaldosteronism", "name": "SPIRONOLACTONE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.2 Diuretics", "2.2.3 Potassium-sparing diuretics and aldosterone antagonists", "Aldosterone antagonists"], "cautions": "Cautions\u00a0potential metabolic products carcinogenic\r\nin rodents; elderly; monitor electrolytes\u2014discontinue if hyperkalaemia\r\noccurs (in severe heart failure monitor potassium\r\nand creatinine 1 week after initiation and after any dose increase,\r\nmonthly for first 3 months, then every 3 months for 1 year, and then\r\nevery 6 months); acute porphyria (section 9.8.2); interactions: Appendix 1\r\n(diuretics)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances, hepatotoxicity;\r\nmalaise, confusion, drowsiness, dizziness, gynaecomastia, benign breast\r\ntumour, breast pain, menstrual disturbances, changes in libido, hypertrichosis,\r\nelectrolyte disturbances including hyperkalaemia (discontinue) and\r\nhyponatraemia, acute renal failure, hyperuricaemia, leucopenia, agranulocytosis,\r\nthrombocytopenia, leg cramps, alopecia, rash, Stevens-Johnson syndrome", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2371.htm", "doses": ["Oedema and ascites in cirrhosis of the liver, 100\u2013400\u00a0mg\r\ndaily, adjusted according to response", "Malignant ascites, initially 100\u2013200\u00a0mg daily, increased to\r\n400\u00a0mg daily if required; maintenance dose adjusted according to response", "Nephrotic syndrome, 100\u2013200\u00a0mg daily", "Oedema in congestive heart failure, initially 100\u00a0mg (range\r\n25\u2013200\u00a0mg) daily in single or divided doses; maintenance dose adjusted\r\naccording to response", "Moderate to severe heart failure (adjunct), initially 25\u00a0mg\r\nonce daily, increased according to response to max. 50\u00a0mg once daily\r\n(see section 2.5.5)", "Resistant hypertension (adjunct), 25\u00a0mg once daily [unlicensed\r\nindication] (see section 2.5)", "Primary hyperaldosteronism in patients awaiting surgery, 100\u2013400\u00a0mg\r\ndaily; long-term maintenance if surgery inappropriate, use lowest\r\neffective dose", "child under 18 years\r\nsee BNF for Children"], "pregnancy": "Pregnancy\u00a0use only if potential benefit outweighs risk\u2014feminisation\r\nof male fetus in animal studies"}]